User login
Key clinical point: Lebrikizumab demonstrated long-term efficacy and a safety profile consistent with that observed in previous trials in adolescents with moderate-to-severe atopic dermatitis (AD).
Major finding: At week 52, 62.6% and 81.9% of patients achieved an Investigator’s Global Assessment score of 0 or 1 with a ≥2-point reduction from baseline and an Eczema Area and Severity Index-75 response, respectively. Adverse events were mostly mild or moderate in severity and led to treatment discontinuation in 2.4% of patients.
Study details: This open-label phase 3 trial, ADore, included 206 adolescents (age ≥12 to <18 years) with moderate-to-severe AD who received lebrikizumab subcutaneously (500-mg loading dose at baseline and week 2, followed by 250 mg every 2 weeks).
Disclosures: This study was funded by Dermira, Inc., a wholly owned subsidiary of Eli Lilly and Company. Some authors declared receiving research grants or consulting, advisory board, or speaker honoraria from or serving as consultants, speakers, or investigators for Eli Lilly and others. Six authors declared being former or current employees or shareholders of Eli Lilly.
Source: Paller AS et al. Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: A 52-week, open-label, phase 3 study. Dermatol Ther (Heidelb). 2023;13(7):1517-1534 (Jun 15). Doi: 10.1007/s13555-023-00942-y
Key clinical point: Lebrikizumab demonstrated long-term efficacy and a safety profile consistent with that observed in previous trials in adolescents with moderate-to-severe atopic dermatitis (AD).
Major finding: At week 52, 62.6% and 81.9% of patients achieved an Investigator’s Global Assessment score of 0 or 1 with a ≥2-point reduction from baseline and an Eczema Area and Severity Index-75 response, respectively. Adverse events were mostly mild or moderate in severity and led to treatment discontinuation in 2.4% of patients.
Study details: This open-label phase 3 trial, ADore, included 206 adolescents (age ≥12 to <18 years) with moderate-to-severe AD who received lebrikizumab subcutaneously (500-mg loading dose at baseline and week 2, followed by 250 mg every 2 weeks).
Disclosures: This study was funded by Dermira, Inc., a wholly owned subsidiary of Eli Lilly and Company. Some authors declared receiving research grants or consulting, advisory board, or speaker honoraria from or serving as consultants, speakers, or investigators for Eli Lilly and others. Six authors declared being former or current employees or shareholders of Eli Lilly.
Source: Paller AS et al. Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: A 52-week, open-label, phase 3 study. Dermatol Ther (Heidelb). 2023;13(7):1517-1534 (Jun 15). Doi: 10.1007/s13555-023-00942-y
Key clinical point: Lebrikizumab demonstrated long-term efficacy and a safety profile consistent with that observed in previous trials in adolescents with moderate-to-severe atopic dermatitis (AD).
Major finding: At week 52, 62.6% and 81.9% of patients achieved an Investigator’s Global Assessment score of 0 or 1 with a ≥2-point reduction from baseline and an Eczema Area and Severity Index-75 response, respectively. Adverse events were mostly mild or moderate in severity and led to treatment discontinuation in 2.4% of patients.
Study details: This open-label phase 3 trial, ADore, included 206 adolescents (age ≥12 to <18 years) with moderate-to-severe AD who received lebrikizumab subcutaneously (500-mg loading dose at baseline and week 2, followed by 250 mg every 2 weeks).
Disclosures: This study was funded by Dermira, Inc., a wholly owned subsidiary of Eli Lilly and Company. Some authors declared receiving research grants or consulting, advisory board, or speaker honoraria from or serving as consultants, speakers, or investigators for Eli Lilly and others. Six authors declared being former or current employees or shareholders of Eli Lilly.
Source: Paller AS et al. Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: A 52-week, open-label, phase 3 study. Dermatol Ther (Heidelb). 2023;13(7):1517-1534 (Jun 15). Doi: 10.1007/s13555-023-00942-y